HEAD TO HEAD COMPARISONS AT 2, 4, AND 7 MONTHS, FOLLOWING STANDARD AND COMBINED PHID-CV10 AND PCV13 SCHEDULES. (ID 429)

Session Name
Vaccines - Pneumococcal Vaccines Development
Presenter
  • Amanda J. Leach, Australia
Authors
  • Amanda J. Leach, Australia
  • Nicole Wilson, Australia
  • Jemima Beissbarth, Australia
  • Kim E. Mulholland, Australia
  • Mathuram Santosham, United States of America
  • Peter McIntyre, Australia
  • Paul V. Licciardi, Australia
  • Mark Chatfield, Australia
  • Victor Oguoma, Australia
  • Jonathan Carapetis, Australia
  • Sue Skull, Australia
  • Heidi Smith-Vaughan, Australia
  • Vicki Krause, Australia
  • Ross Andrews, Australia
  • Peter Morris, Australia
  • Paul Torzillo, Australia

Abstract

Background

Australian Aboriginal children are at high risk of early infection withStreptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi). We evaluated immunogenicity against 10 shared serotypes of a 4-dose combination schedule of PHiD-CV10 at 1-2-4 months plus PCV13 at 6 months, compared with standard 2-4-6 month schedules.

Methods

Infants were allocated (1:1:1) at 28 to 38 days of age, to 3-dose schedules of PCV13 (P) or PHiD-CV10 (S) at 2-4-6 months (_PPP or _SSS), or a combination schedule at 1-2-4-6 months (SSSP). Immunogenicity was measured at 2, 4, and 7 months.

Results

At 2 months the SSSP combination was superior to pre-vaccination (VTs other than 6B, 19F, or 23F). At 4 months SSSP was superior to _PPP (9 VTs) and _SSS (7 VTs), and _SSS was superior to _PPP (8 VTs). At 7 months, SSSP was superior to _PPP (1, 6B, 9V, 19F and 23F) and _SSS (8 VTs), and _PPP was superior to _SSS (8 VTs). OPA supports the SSSP schedule, particularly against 1, 6B, and 23F.

Conclusions

The 1-2-4-6 month schedule (SSSP) was superior at 2, 4, and 7 months of age compared to _SSS or _PPP, particularly for 1, 6B, and 23F at 7 months. At 4 months, _SSS was superior to _PPP.

Hide